These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21112854)

  • 21. [Biomarkers, tumor markers and prognostic markers in breast cancer].
    Kurebayashi J
    Nihon Rinsho; 2006 Mar; 64(3):461-6. PubMed ID: 16529036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
    Saijo N
    Cancer Treat Rev; 2012 Feb; 38(1):63-7. PubMed ID: 21652149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biomarkers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
    Kaufmann M; Pusztai L;
    Cancer; 2011 Apr; 117(8):1575-82. PubMed ID: 21472705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designing the future shape of breast cancer diagnosis, prognosis and treatment.
    Dowsett M
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S27-9. PubMed ID: 15597218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
    Yaal-Hahoshen N; Shina S; Leider-Trejo L; Barnea I; Shabtai EL; Azenshtein E; Greenberg I; Keydar I; Ben-Baruch A
    Clin Cancer Res; 2006 Aug; 12(15):4474-80. PubMed ID: 16899591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
    Huber KE; Carey LA; Wazer DE
    Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular predictors of local tumor control in early-stage breast cancer.
    Miyamoto DT; Harris JR
    Semin Radiat Oncol; 2011 Jan; 21(1):35-42. PubMed ID: 21134652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardization of immunobioassays as surrogate endpoints.
    Masood S
    J Cell Biochem Suppl; 1994; 19():28-35. PubMed ID: 7823602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.